Maeda I, Tajima S, Kanemaki Y, Tsugawa K, Takagi M
Use of immunohistochemical analysis of CK5/6, CK14, and CK34betaE12 in the differential diagnosis of solid papillary carcinoma in situ from intraductal papilloma with usual ductal hyperplasia of the breast
SAGE Open Medicine, 2018;6：1-8.
Ito Y, Tsuda T, Minatogawa H, Kano S, Sakamaki K, Ando M, Tsugawa K, Kojima Y, Furuya N, Matsuzaki K, Fukuda M, Sugae S, Ohta I, Arioka H, Tokuda Y, Narui K, Tsuboya A, Suda T, Morita S, Boku N, Yamanaka T, Eguchi Nakajima T
Placebo-Controlled, Double-Blinded Phase Ⅲ study comparing dexamethasone on Day 1 with dexamethasone on Days 1 to 3 with combined Neurokinin-1 receptor antagonist and palonosetron in high-emetogenic chemotherapy
J Clin Oncol, 2018;36(10)：1000-1006.
Onishi H, Udagawa C, Kubo M, Nakamura S, Akashi-Tanaka S, Kuwayama T, Watanabe C, Takamaru T, Takei H, Ishikawa T, Miyahara K,Matsumoto H, Hasegawa Y, Momozawa Y, Low SK, Kutomi G, Shima H, Satomi F, Okazaki M, Zaha H, Onomura M, Matsukata A, Sagara Y, Baba S, Yamada A, Shimada K, Shimizu D, Tsugawa K, Shimo A, Hartman M, Chan CW, Lee SC, Endo I, Zembutsu H
A genome-wide association study identifies three novel genetic markers for response to tamoxifen:A prospective multicenter study
PloS One, 2018;13(8)：e0201606.
Yamamoto Y, Iwata H, Ueno T, Taira N, Kashiwada M, Tada H, Tsugwa K, Toyama T, Niikura N, Hara F, Fujisawa T, Yoshinami T, Saji S, Takano T, Masuda N, Morita S, Toi M, Ohno S
A randomized, open-label, Phase Ⅲ trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy:the Japan breast cancer research Group-M05 PRESIOUS study.
Japanese Journal of Clinical Oncology, 2018;48(9)：855-859.
Kojima Y, Kawamoto H, Nishikawa T, Hayami R, Shimo A, Haku E, Akiyama K, Tsugawa K
Feasibility study of weekly nanoparticle Albumin-Bound Paclitaxel(150mg/m2)followed by fluorouracil, epirubicin,and cyclophosphamide therapy as neoajuvant chemotherapy for HER2-negative Breast Cancer.
Clinical breast cancer, 2018;18(5)：374-379.
Kuwayama T, Nakamura S, Hayashi N, Takano T, Tsugawa K, Sato T, Kitani A, Okuyama H, Yamauchi H
Randomized multicenter phaseⅡtrial of neoadjuvant therapy comparing weekly Nab-paclitaxel followed by FEC with docetaxel followed by FEC in HER2-early-stage breast cancer.
Clinical breast cancer, 2018;18(6)：474-480.
Iwatani T, Noto S, Tsugawa K
An international comparative study on EuroQol-5-Dimension Questionnaire(EQ-5D)tariff score between the UK and Japan.
Japan Journal of Medicine, 2018;1(6)：291-296.
Johmura Y, Maeda I, Suzuki N, Wu W, Goda A, Morita M, Yamaguchi K, Yamamoto M, Nagasawa S, Kojima Y, Tsugawa K, Inoue N, Miyoshi Y, Osako T, Akiyama F, Maruyama R, Inoue J, Furukawa Y, Ohta T, Nakanishi M
Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancer.
The Journal of clinical investigation, 2018;128(12)：5603-5619.
Fijikawa Y, Mukai H, Saeki T, Ro J, Lin YC, Nagai SE, Lee KS, Watanabe J, Ohtani S, Kim SB, Kuroi K, Tsugawa K, Tokuda Y, Iwata H, Park YH, Yang Y, Nambu Y
A multi-national, randomised, open-label, parallel, phaseⅢ non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients.
British journal of cancer, 2019;120：475-480.
Kojima Y, Yoshie R, Kawamoto H, Shimo A, Uejima T, Iwatani T, Motoyoshi A, Kanemaki Y, Boku N, Tsugawa K
Trastuzumab emtansine(T-DM1)plus S-1 in patients with Trastuzumab-Pretreated HER2-Positive advanced or metastatic breast cancer:A Phase lb study.
Oncology, 2019：1-9.
② 総説又は症例解説
Wada A, Hayashi N, Endo F, Tsunoda H, Yoshida A, Suzuki K, Nakamura S, Yamauchi H
Repeat recurrence and malignant transtion of phyllodes tumors of the breast.
Breast Cancer, 2018;25：736-741.
Tajima S, Maeda I, Chosokabe M, Kishimoto K, Ono T, Tsugawa K, Takagi M
Breast Benign Papillary Lesions: Mini-Review.
Clinical Pathology ＆ Research Journal, 2018;2(1)：000111.
③ 症例報告
Takishita M, Saji H, Marushima H, Miyazawa T, Kimura H, Sakai H, Wakiyama Y, Tsuda M, Kojima K, Hoshikawa M, Doi M, Takagi M, Nakamura H
Thymic large-cell neuroendocrine carcinoma:a case report and review of a japanese case series.
Annals of clinical case reports, 2018;3：1-3.
Kojima Y, Kawamoto H, Shimo A, Haku E, Kanemaki Y, Yoshie R, Motoyoshi A, Uejima T, Iwatani T, Tsugawa K
A phase 1b study of S-1 combined with trntuzmab emtansine(T-DM1)for HER2 positive metastatic breast cancer.
第16回日本臨床腫瘍学会学術総会, 2018.
Shimizu C, Kataoka A, Kuwayama A, Kojima Y, Pagani O, Partridge AH, Azim Jr HA, Peccatori FA
Trial in progress:Positive(IBCSG48-14/BIG8-13/A221405)A study evalating pregnancy,desease outcome and safety of interrupting endcrine therapy for premenopausal women with endcrine responsIVEbreast cancerwho desire pregnancy.
第9回日本がん・生殖医療学会学術集会, 2019.
② 国際学会
Katsumata K, Segami K, Tazo M, Hoshino H, Katayama M, Kobayashi S, Koizumi S, Otsubo T
A case of intraperitoneal bleeding caused by rupture of a right gastropiploic artery aneurysm due to segmental arterial mediolysis. The 64th annual congress of international college og surgeons JAPAN SECTION, 2018.
Tazo M, Kojima Y, Tsugawa K
Retrospective study of axillary management after preoperative chemotherapy amongst breast cancer patients in our institute.
ISNS 2018 international sentinel node society biennial meeting, 2018.
Iwatani
Can we apply the utility prediction mahematical model(Lloyd’s Model) for recurrent metastatic breast cancer to Japanese patients?. ISPOR 21st anuual European congress, 2018.
Hara M, Udagawa C, Shimo A, Kojima Y, Yoshie R, Zaha H, Abe N, Motonari T, Unesoko M, Tamura K, Shimoi T, Yoshida M, Yoshida T, Mushiroda T, Tsugawa K, Zembutsu H
Genome-wide association study to identify novel biomarkers for trastuzumab-induced cardiotoxicity.
ASHG 2018 Annual Meeting, 2018.
